A Study of Lebrikizumab in Patients Whose Asthma is Uncontrolled With Inhaled Corticosteroids and A Second Controller Medication (LUTE)

Inclusion Criteria: * Adult patients, 18 to 75 years of age at Visit 1 * Asthma diagnosis for \>/= 12 months prior to the start of screening (Visit 1) * Bronchodilator response during screening * Pre-bronchodilator FEV1 40%-80% of predicted during screening * On ICS (inhaled corticosteroids) 500-2000 mcg/day of fluticasone propionate DPI or equivalent for \>/= 6 months prior to the start of screening (Visit 1) with no anticipated changes throughout the study * On an eligible second controller medication (LABA, LAMA, LTRA or theophylline within the prescribed dosing range) * Uncontrolled asthma as defined by protocol both during screening period and at time of randomization * Chest X-ray or computed tomography (CT) scan obtained within 12 months prior to screening or chest X-ray during screening period confirming the absence of other lung disease * Demonstrated adherence with controller medication during the screening period Exclusion Criteria: * History of severe allergic or anaphylactic reaction to a biologic agent or known hypersensitivity to any component of the lebrikizumab injection * Use of zileuton or roflumilast within 6 months prior to screening * Maintenance oral corticosteroid therapy, defined as daily or alternate day oral corticosteroid maintenance therapy within the 3 months prior to Visit 1 * Treatment with systemic (oral, intravenous or intramuscular) corticosteroids within the 4 weeks prior to Visit 1 * Major episode of infection within 4 weeks prior to Visit 1 or treatment with oral antibiotics within 2 weeks prior to Visit 1 * Active parasitic infection within the 6 months prior to Visit 1 * Active tuberculosis requiring treatment within the 12 months prior to Visit 1 * Known immunodeficiency, including, but not limited to, HIV infection * Evidence of acute or chronic hepatitis or known liver cirrhosis * History of cystic fibrosis, chronic obstructive pulmonary disease, and/or other clinically significant lung disease other than asthma * Known malignancy or current evaluation for a potential malignancy * Current smoker or former smoker with a history \>10 pack years * History of alcohol, drug or chemical abuse * Initiation or change in allergen immunotherapy within 3 months prior to Visit 1 * Use of biologic therapy including omalizumab during 6 months prior to Visit 1 * Receipt of live/attenuated vaccine within 4 weeks prior to Visit 1 * Pregnant or lactating women * Body mass index (BMI) \> 38 kg/m2 * Body weight \< 40 kg